Thrombotic cardiac tamponade after transseptal puncture

George D. Katritsis, MBChB, BSc, Theodoros Zografos, MD, Eleftherios Giazitzoglou, MD, Demosthenes G. Katritsis, MD, PhD

From † John Radcliffe Hospital, The Oxford University Clinical Academic Graduate School, Oxford, United Kingdom, ‡ Athens Euroclinic, Athens, Greece, and †Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Introduction

Hemopericardium and subsequent tamponade is an insidious complication of catheter ablation procedures for atrial fibrillation (AF).

Case report

An 84-year-old woman was admitted for catheter ablation of long-standing, permanent AF. Her previous medical history consisted of long-standing arterial hypertension and persistent AF diagnosed 3 years ago. She had undergone circumferential pulmonary vein (PV) isolation (ie, linear ablation around the PV antra with subsequent verification of PV isolation) and repeat ablation of a macroreentrant atrial tachycardia around the left superior PV. She had remained in sinus rhythm for 2 months postablation, and paroxysmal AF was detected after cessation of amiodarone therapy. On admission, clinical examination was unremarkable. She was in sinus rhythm, her blood pressure was 130/90 mm Hg, and echocardiography revealed normal left ventricular ejection fraction (65%), left atrial diameter of 32 mm, and grade I mitral and tricuspid regurgitation. She had no signs of myocardial hypertrophy or pericardial thickening. Her medications consisted of irbesartan/hydrochlorothiazide, bisoprolol, and low-dose aspirin. Her warfarin had been replaced with subcutaneous enoxaparin 3 days ago, and her international normalized ratio was 1.1.

She was taken to the electrophysiology laboratory for circumferential PV isolation of all PVs and ganglionated plexi ablation, according to our standard protocol.1 Transseptal puncture was performed at a high atrial septum site, and difficulty was encountered in crossing the septum, which had become fibrosed after the previous 2 procedures. Immediately afterward and before heparin was given, the patient felt unwell. She became relatively hypotensive (80/50 mm Hg), and clinical signs of tamponade were obvious. Echocardiography demonstrated an echolucent space surrounding the left atrium and left ventricle, without ongoing filling. Compression of the right atrium, considered to be a moderate pericardial effusion, with impaired right ventricular filling and mitral flow velocity paradoxus. Pericardiocentesis was attempted immediately under fluoroscopic and echocardiographic guidance, without success. Although the needle was clearly within the pericardial space, no blood was drawn. An emergency thoracotomy was performed, which revealed a large clot within the pericardium adjacent to the lateral wall of the left atrium and left ventricle, without ongoing bleeding. The patient experienced immediate relief and recovered uneventfully. Subsequent thrombophilia testing, including factor V Leiden and prothrombin mutations, and antiphospholipid antibodies revealed a borderline lupus anticoagulant, without anticardiolipin and anti–β₂-glycoprotein-I antibodies (Table 1).2,3 The patient refused further ablation and was placed on oral anticoagulation.

Discussion

Even though ablation procedures have evolved to offer increased success rate and reduced complications, hemorrhagic events remain an insidious complication. Among the complications, the development of hemopericardium and subsequent tamponade has been documented in approximately 1.2% of patients.4–6 In most cases, pericardiocentesis and percutaneous drainage can provide effective treatment; however, surgical intervention is sometimes needed, mainly in the setting of uncontrolled pericardial bleeding.

Two underrecognized clinical entities that can lead to tamponade and can be difficult to identify with transthoracic echocardiography as well as to treat with percutaneous drainage are loculated hemopericardium (eg, in patients with prior cardiac surgery and preexisting intrapericardial adhesions) and coexisting huge pleural effusion.7,8 Immediate pericardial thrombus is an extremely rare possibility because small amounts of blood in the pericardial space do not result in immediate clot formation. In fact, intracavitary blood has long been known to be incoagulable,9 and even though evidence for pericardial effusions does not exist, extrapolation of hemotherax characteristics suggests that hemopericardium is defibrinated and thrombocytopenic, and contains elevated levels of D-dimers.10 Accordingly, early development of pericardial thrombus is an unlikely finding.
Pericardial tamponade is an extremely rare possibility, but it may occur and, if accompanied by tamponade physiology, would require surgical evacuation.

Female gender and older age confer increased complication risk.

Repeat transseptal punctures are associated with a higher risk for cardiac tamponade because of scarring of the previously perforated septum. When a dif-

Furthermore, on occasion a higher puncture position or a larger-curve Brockenbrough needle may be needed. In the presence of a dilated left atrium, a technique used in mitral valvuloplasty may be of help. The issue of uninterrupted anticoagulation with either a vitamin K antagonist or Xa inhibitor, which appears to be safer than bridging to heparin, or no anticoagulation 2–3 days before ablation also may be raised. However, the limited experience of just 1 case does not allow any definitive conclusions in this respect.

Table 1 Thrombophilia testing

1. Blood cell count with peripheral smear, hepatic and renal function, and serum protein electrophoresis.
2. Genetic testing for factor V Leiden and prothrombin G20210A mutations, especially if an inherited thrombophilia is suspected.
3. Antiphospholipid antibodies (eg, lupus anticoagulant, anticardiolipin antibodies, anti-β2-glycoprotein-1 antibodies). Testing for antiphospholipid antibodies requires confirmation 12 weeks after an initial positive result.
4. Antithrombin, protein C, and protein S, at least 6 weeks after the event.

Note: Direct leukocyte genomic DNA testing for factor V Leiden and prothrombin G20210A mutations is unaffected by anticoagulation therapy. Heparin therapy can lower antithrombin activity and antigen levels and can impair interpretation of clot-based assays for a lupus anticoagulant. A delay of at least 5 days after heparin is stopped before testing usually is feasible. Warfarin therapy reduces the activity and antigen levels of vitamin K-dependent factors, including proteins C and S (up to 6 weeks). Non-vitamin K-dependent oral anticoagulants (NOACs) may cause false-positive lupus anticoagulant (dilute Russell viper venom time) test results and falsely low antithrombin activity. Testing should be delayed until the effects of warfarin or NOACs therapy have resolved.

References
1. Katritsis DG, Pokushalov E, Romanov A, Giaitzagouglo E, Siontis GCM, Po SS, Camm AJ, Ioannidis JPA. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol 2013;62:2318–2325.
2. Cohoon KP, Heit JA. Inherited and secondary thrombophilia. Circulation 2014;129:254–257.
3. Piazza G. Thrombophilia testing, recurrent thrombosis, and women's health. Circulation 2014;130:283–287.
4. Katritsis SG, Siontis GCM, Giaitzagouglo E, Fragakis N, Katritsis DG. Complications of transseptal catheterization for different cardiac procedures. Int J Cardiol 2013;168:5352–5354.
5. Banan TS, Songnarrangsing K, Chugh A, et al. Prevalence and predictors of complications of radiofrequency catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiology 2011;22:626–631.
6. Spragg DD, Dalal D, Cheema A, Scherr D, Chalukuri K, Cheng A, Henrikson C, Marine JE, Berger RD, Dong J, Calkins H. Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiology 2008;19:627–611.
7. Saito Y, Donohue A, Attai S, Vahdat A, Brar R, Handapangoda I, Chandraratna PA. The syndrome of cardiac tamponade with "small" pericardial effusion. Echocardiography 2008;25:321–327.
8. Koruth JS, d’Avila A. Management of hemopericardium related to percutaneous epicardial access, mapping, and ablation. Heart Rhythm 2011;8:1652–1657.
9. Broadie TA, Bendick PJ, Lowe DK, Yaw PB, Med AE. Clotting competence of intracavitary blood in trauma victims. Ann Emerg Med 1981;10:127–130.
10. Smith WZ, Harrison HB, Saltanick M, Higgins R a, Ortiz A, Olson JD, Schwacha MG, Harrison CR, Ayedotje JD, Stewart RM, Deni DL. A small amount can make a difference: a prospective human study of the paradoxical coagulation characteristics of hemotheras. Am J Surg 2013;206:904–909.
11. Aldhoon B, Wichterle D, Peichl P, Cháik R, Kautzner J. Complications of catheter ablation for atrial fibrillation in a high-volume centre with the use of intracardiac echocardiography. Europace 2013;15:24–32.
12. Hu YF, Tai CT, Lin YJ, Chang SL, Lo LW, Wongcharoen W, Udyavar AR, Tuan T, Chen SA. The change in the florescropy-guided transseptal puncture site and difficult punctures in catheter ablation of recurrent atrial fibrillation. Europace 2008;10:276–279.
13. Hung JS. Atrial septal puncture technique in percutaneous transvenous mitral commissurotomy: mitral valvuloplasty using the Inoue balloon catheter technique. Cathet Cardiovasc Diagn 1992;26:275–284.
14. Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014;129:2638–2644.
15. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2014;63:982–988.